Objective Vaccines based on viral structural products (Env/Gag/Pol) alone have failed to prevent infection by HIV/SIV. Vaccines based on viral regulatory gene products (Tat/Rev/Nef) have contained virus replication preventing disease onset.A vaccine combining both (combined vaccine) is likely to be superior to the formers since it induces immune responses targeting both early and late viral products. The mission of AVIP is to develop novel preventive and therapeutic vaccines to be tested in phase I trials in Europe, that are suitable for future testing in phase II/III trials in Developing Countries (DC), and to foster training, technology transfer and community involvement among EU and DC.To ensure completion of the program, priority has been given to vaccine combinations containing single antigens that are already approved for human use and in phase I studies and with proven efficacy in animal models.Therefore AVIP specific objectives are to conduct:1.Preventive and therapeutic phase I trials in Europe with 4 novel combined vaccines. These will be first tested in preclinical models to optimise the formulation and the vaccination protocols, and then will enter phase I trials.2.Feasibility studies and technology transfer in DC for future phase II/III trials within the European and Developing Countries Clinical Trials Programme (EDCTP).3.Training in EU countries and DC. To this goal, the AVIP International School will be established.4.Community involvement both in EU countries and DC to ensure the correct ethical information of the volunteers, counselling, quality of life evaluation and risk assessment. AVIP objectives will be implemented by an ad hoc management structure which will oversees the science, training, business and administrative activities of AVIP. Fields of science natural sciencesbiological sciencesmicrobiologyvirologymedical and health sciencesbasic medicineimmunologymedical and health scienceshealth sciencesinfectious diseasesRNA virusesHIVmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines Keywords AIDS CLINICAL TRIALS HIV HIV/AIDS REGULATORY GENES clinical trials regulatory genes Programme(s) FP6-LIFESCIHEALTH - Life sciences, genomics and biotechnology for health: Thematic Priority 1 under the Focusing and Integrating Community Research programme 2002-2006. Topic(s) LSH-2002-2.3.0-1 - Development of an HIV vaccine Call for proposal FP6-2002-LIFESCIHEALTH See other projects for this call Funding Scheme IP - Integrated Project Coordinator ISTITUTO SUPERIORE DI SANITÀ EU contribution No data Address Viale Regina Elena 299 ROME Italy See on map Links Website Opens in new window Total cost No data Participants (18) Sort alphabetically Sort by EU Contribution Expand all Collapse all KAROLINSKA INSTITUTET Sweden EU contribution No data Address STOCKHOLM See on map Links Website Opens in new window Total cost No data HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH Germany EU contribution No data Address Inhoffenstrasse 7 N/A BRAUNSCHWEIG See on map Links Website Opens in new window Total cost No data FIT BIOTECH OYJ PLC Finland EU contribution No data Address Lenkkeilijaenkatu 10 TAMPERE See on map Links Website Opens in new window Total cost No data HELMHOLTZ CENTER MUNICH, GERMAN RESEARCH CENTER FOR ENVIRONMENTAL HEALTH Germany EU contribution No data Address NEUHERBERG See on map Links Website Opens in new window Total cost No data NOVARTIS VACCINES AND DIAGNOSTICS SRL Italy EU contribution No data Address Via Fiorentina 1 SIENA See on map Links Website Opens in new window Total cost No data IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE United Kingdom EU contribution No data Address Exhibition Road LONDON See on map Links Website Opens in new window Total cost No data WITS HEALTH CONSORTIUM (PTY) LTD South Africa EU contribution No data Address Private Bag 2600 HOUGHTON, JOHANNESBURG See on map Links Website Opens in new window Total cost No data UNIVERSITY OF STELLENBOSCH South Africa EU contribution No data Address Adm. Building B, Victoria Street Private Bag STELLENBOSCH See on map Links Website Opens in new window Total cost No data FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR Italy EU contribution No data Address Via Olgettina 60 MILANO See on map Links Website Opens in new window Total cost No data HEALTH PROTECTION AGENCY United Kingdom EU contribution No data Address Central Office - 7th Floor, Holborn Gate - High Holborn 330 LONDON See on map Links Website Opens in new window Total cost No data TERRAMATICA CONSULTING SRL Italy EU contribution No data Address Via Giuseppe Missori 15 ROME See on map Total cost No data UNIVERSITY OF THE WITHWATERSRAND, JOHANNESBURG (MEDICAL RESEARCH COUNCIL, AGINCOURT) South Africa EU contribution No data Address 1 Jan Smuts Avenue Private Bag 3 JOHANNESBURG See on map Links Website Opens in new window Total cost No data MINISTRY OF HEALTH (NATIONAL REFERENCE LABORATORY - MBABANE) South Africa EU contribution No data Address Hospital Hill 8, Mbabane MBABANE See on map Total cost No data COMMISSARIAT À L'ÉNERGIE ATOMIQUE France EU contribution No data Address 31/33 Rue de la Fédération PARIS See on map Links Website Opens in new window Total cost No data UNIVERSITÀ DEGLI STUDI DI MILANO Italy EU contribution No data Address Via Festa del Perdono 7 MILANO See on map Links Website Opens in new window Total cost No data UNIVERSITÀ DEGLI STUDI DI PADOVA Italy EU contribution No data Address Via 8 Febbraio, 2 PADOVA See on map Links Website Opens in new window Total cost No data UNIVERSITÀ DEGLI STUDI DI URBINO "CARLO BO" Italy EU contribution No data Address Via Saffi 2 URBINO See on map Links Website Opens in new window Total cost No data UNIVERSITÀ DI FERRARA Italy EU contribution No data Address Via Savonarola, 9 FERRARA See on map Links Website Opens in new window Total cost No data